stockportfolio.pro
Stocks / EXEL vs JAZZ
EXEL vs JAZZ
Exelixis, Inc. and Jazz Pharmaceuticals plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Exelixis, Inc. (EXEL) | Jazz Pharmaceuticals plc (JAZZ) | |
|---|---|---|
| Market cap | $13.4B | $14.4B |
| Revenue (latest FY) | $2.32B | $4.27B |
| Net income (latest FY) | $782.57M | $-356.15M |
| Revenue growth (5y CAGR) | 18.6% | 12.5% |
| Net margin | 33.7% | -8.3% |
| Return on equity | 36.2% | -8.2% |
| P/E ratio | 17.6 | 2080.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EXEL — free Open JAZZ — freeFrequently asked questions
Which is bigger, EXEL or JAZZ?
Jazz Pharmaceuticals plc is larger by market capitalization — $14.4B versus $13.4B.
Which grows faster, EXEL or JAZZ?
Over the last five fiscal years, Exelixis, Inc. grew revenue faster — 18.6%/yr versus 12.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.